T. Rowe Price Global Value Equity continues to earn our conviction as a compelling option for investors seeking value-oriented global equities exposure. The substantially experienced and stable investment team led by Sebastian Mallet has continued to execute a differentiated and effective investment process efficiently, upholding our confidence in the strategy to deliver long-term outperformance. The strategy’s opportunistic value approach spans the value spectrum and leverages rigorous bottom-up research and effective execution. These attributes provide a robust foundation for the strategy’s ability to deliver risk-adjusted outperformance over the long term, supporting an Above Average rating for the People and Process pillars.
T. Rowe Price Global Value Equity Fund TRGVX
- NAV / 1-Day Return $24.27 / −0.08 %
- Fund Size $312.0M
- Adjusted Expense Ratio 0.890%
- Net Expense Ratio 0.890%
- Fee Level: Distribution Average
- Share Class Type No Load
- Morningstar Category Global Large-Stock Value
- Equity Style Box (Funds) Large Value
- Minimum Initial Investment $2,500
- Investment Status Open
- TTM Yield 1.66%
- Turnover Ratio 77%
Morningstar’s Analysis TRGVX
Will TRGVX outperform in the future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 25.7
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
Microsoft Corp | 6.82 | 21M | Technology |
Meta Platforms Inc Class A | 3.21 | 10M | Communication Services |
Alphabet Inc Class C | 3.03 | 9M | Communication Services |
ExxonMobil Holdings Corp | 2.13 | 7M | Energy |
JPMorgan Chase & Co | 2.00 | 6M | Financial Services |
AstraZeneca PLC | 1.98 | 6M | Healthcare |
Micron Technology Inc | 1.81 | 6M | Technology |
Gilead Sciences Inc | 1.73 | 5M | Healthcare |
Deere & Co | 1.51 | 5M | Industrials |
AbbVie Inc | 1.51 | 5M | Healthcare |